Latest Strategy News

Metro Mining’s latest update reveals a decline in Ore Reserves and Resources at Bauxite Hills Mine due to 2024 mining activity, with no new exploration additions. The company plans a significant capital expansion to boost production capacity.

Elixinol Wellness Limited reported a robust FY24 performance, achieving an 81% increase in revenue and significantly narrowing its losses. The company is now focused on scaling its direct-to-consumer channels and operational efficiencies to reach profitability in 2025.

Waratah Minerals has mobilised a third drill rig to its Spur Gold-Copper Project in New South Wales, targeting high-priority porphyry copper-gold zones and expanding exploration along the Spur Gold Corridor.

Bryah Resources has requested an immediate suspension of its shares on the ASX as it prepares to announce a significant acquisition. The suspension follows a recent trading halt and is expected to last until the announcement or the resumption of trading on May 21.

Atomo Diagnostics has released a Target Market Determination for a new capital raising involving options and shares, including a $1 million Share Purchase Plan and placement offer. The move targets eligible Australian shareholders and aims to bolster the company’s financial position amid a speculative investment environment.

Atomo Diagnostics Limited has announced a capital raising initiative comprising a Share Purchase Plan (SPP) and a Placement, aiming to raise up to $1 million through the SPP and additional funds via a Placement, subject to shareholder approval at a June 23 meeting.

TZ Limited has received a second purchase order from Wesco Anixter on behalf of Microsoft, reinforcing its growing role in global data centre security deployments. The combined orders now total approximately AUD 585,000, highlighting strong momentum in TZ’s expansion across key international markets.

OFX Limited reported a resilient FY25 with steady revenue and strong cash flow, while advancing its New Client Platform and strategic market expansion despite economic headwinds.

OFX Group reported a slight revenue decline in FY25 but is doubling down on its New Client Platform rollout to drive future growth and diversify revenue streams.

OFX Group Limited posted a 3.4% drop in revenue for FY25, with profits falling over 18%, while continuing its active share buy-back strategy.

Avecho Biotechnology has expanded its pivotal Phase III clinical trial for a CBD insomnia treatment by adding new recruitment sites and partnering with pharmaceutical giant Sandoz to boost patient enrolment and regulatory progress.

Midas Minerals has locked in $6.5 million through a two-tranche placement to fund its strategic acquisition and exploration of the Otavi Copper Project in Namibia, alongside advancing its broader project portfolio.